<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832828</url>
  </required_header>
  <id_info>
    <org_study_id>PI-4321</org_study_id>
    <nct_id>NCT04832828</nct_id>
  </id_info>
  <brief_title>Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive</brief_title>
  <official_title>Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Madrid</source>
  <brief_summary>
    <textblock>
      The presence of the described silent hypoxia in subjects diagnosed with COVID19 highlights&#xD;
      the need for valid tools to assess respiratory capacity. The Roth test has been associated&#xD;
      with acceptable sensitivity and specificity criteria in patients with previous respiratory&#xD;
      pathology; however, its validity in this type of patient has not been proven.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">November 28, 2020</completion_date>
  <primary_completion_date type="Actual">November 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>12 weeks</time_frame>
    <description>The pulseoximeter percentage value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Roth´s test</measure>
    <time_frame>12 weeks</time_frame>
    <description>The level described in the test</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">114</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID+ Group</arm_group_label>
    <description>Patients diagnosed with Covid19 positive in last 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Roth´s Test</intervention_name>
    <description>Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.</description>
    <arm_group_label>COVID+ Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged 18 to 90 years were recruited by non-probabilistic convenience sampling in&#xD;
        Primary Health Care Centres of the Primary Health Care Management of SERMAS and the&#xD;
        Intensive Care Unit of the University Hospital of Gran Canaria Doctor Negrín of the Canary&#xD;
        Health Service&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. having been diagnosed as COVID-19 positive and with symptoms compatible with&#xD;
             Sars-Cov-2 infection in the last 7 days prior to assessment,&#xD;
&#xD;
          2. having an understanding of Spanish,&#xD;
&#xD;
          3. and having no history of respiratory pathology prior to the current infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CS Entrevías</name>
      <address>
        <city>Madrid</city>
        <zip>28053</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Madrid</investigator_affiliation>
    <investigator_full_name>Raúl Ferrer-Peña</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

